Royal Bank of Canada’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-11,894
| Closed | -$565K | – | 7123 |
|
|
2025
Q3 | $565K | Sell |
11,894
-4,826
| -29% | -$234K | ﹤0.01% | 4395 |
|
|
2025
Q2 | $893K | Sell |
16,720
-9,882
| -37% | -$449K | ﹤0.01% | 4000 |
|
|
2025
Q1 | $1.08M | Buy |
26,602
+3,263
| +14% | +$138K | ﹤0.01% | 3414 |
|
|
2024
Q4 | $649K | Buy |
23,339
+241
| +1% | +$7.3K | ﹤0.01% | 3873 |
|
|
2024
Q3 | $662K | Buy |
23,098
+222
| +1% | +$5.79K | ﹤0.01% | 3874 |
|
|
2024
Q2 | $537K | Buy |
22,876
+5,410
| +31% | +$116K | ﹤0.01% | 3955 |
|
|
2024
Q1 | $441K | Sell |
17,466
-12,936
| -43% | -$311K | ﹤0.01% | 4061 |
|
|
2023
Q4 | $710K | Buy |
30,402
+11,737
| +63% | +$231K | ﹤0.01% | 3959 |
|
|
2023
Q3 | $944K | Buy |
18,665
+13,815
| +285% | +$643K | ﹤0.01% | 3490 |
|
|
2023
Q2 | $226K | Buy |
4,850
+1,525
| +46% | +$69.9K | ﹤0.01% | 4629 |
|
|
2023
Q1 | $127K | Sell |
3,325
-1,987
| -37% | -$88.6K | ﹤0.01% | 4987 |
|
|
2022
Q4 | $292K | Buy |
5,312
+2,707
| +104% | +$116K | ﹤0.01% | 4553 |
|
|
2022
Q3 | $89K | Buy |
2,605
+235
| +10% | +$3.6K | ﹤0.01% | 5379 |
|
|
2022
Q2 | $22K | Sell |
2,370
-1,423
| -38% | -$14.8K | ﹤0.01% | 6060 |
|
|
2022
Q1 | $53K | Sell |
3,793
-3,830
| -50% | -$67.1K | ﹤0.01% | 6048 |
|
|
2021
Q4 | $161K | Buy |
7,623
+3,258
| +75% | +$72.3K | ﹤0.01% | 5546 |
|
|
2021
Q3 | $97K | Buy |
4,365
+393
| +10% | +$8.9K | ﹤0.01% | 5725 |
|
|
2021
Q2 | $99K | Buy |
3,972
+1,320
| +50% | +$37.1K | ﹤0.01% | 5619 |
|
|
2021
Q1 | $77K | Buy |
2,652
+821
| +45% | +$24.9K | ﹤0.01% | 5624 |
|
|
2020
Q4 | $48K | Buy |
1,831
+740
| +68% | +$20.6K | ﹤0.01% | 5673 |
|
|
2020
Q3 | $34K | Hold |
1,091
| – | – | ﹤0.01% | 5505 |
|
|
2020
Q2 | $27K | Sell |
1,091
-49
| -4% | -$1.12K | ﹤0.01% | 5465 |
|
|
2020
Q1 | $24K | Buy |
1,140
+396
| +53% | +$8.49K | ﹤0.01% | 5458 |
|
|
2019
Q4 | $17K | Buy |
744
+700
| +1,591% | +$14.5K | ﹤0.01% | 5919 |
|
|
2019
Q3 | $1K | Buy |
+44
| New | +$1.02K | ﹤0.01% | 6385 |
|
Other funds holding AKRO
Royal Bank of Canada's AKRO Position: Q4 2025 in Review
Royal Bank of Canada sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 11,894 shares — an estimated $565K sold.
Royal Bank of Canada first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $1.08M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Royal Bank of Canada reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Royal Bank of Canada sold 11,894 Akero Therapeutics shares in Q4 2025, an estimated $565K.
- Royal Bank of Canada first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Royal Bank of Canada's Akero Therapeutics position peaked at $1.08M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.